Details for Patent: 11,246,866
✉ Email this page to a colleague
Which drugs does patent 11,246,866 protect, and when does it expire?
Patent 11,246,866 protects MAVYRET and is included in one NDA.
Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-one patent family members in twenty-three countries.
Summary for Patent: 11,246,866
Title: | Solid pharmaceutical compositions for treating HCV |
Abstract: | The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion. |
Inventor(s): | Sever; Nancy E. (Northbrook, IL), Westedt; Ulrich (Schriesheim, DE), Lander; Ute (Dannenfels, DE), Schneider; Katrin (Mannheim, DE), Steitz; Benedikt (Kallstadt, DE), Mueller; Thomas (Ludwigshafen, DE), Reul; Regina (Mannheim, DE), Obermiller; Constanze (Heidelberg, DE), Jayasankar; Adivaraha (Naperville, IL), Simon; Michael (Landau, DE), Gao; Yi (Vernon Hills, IL), Hach; Harald (Oberotterbach, DE), Kyeremateng; Samuel (Mannheim, DE), Asmus; Katharina (Neustadt a.d.W., DE), Tong; Ping (Potomoc, MD), Zhu; Donghua (Vernon Hills, IL), Naris; Marius (Downers Grove, IL), Garrett; Colleen (Chicago, IL) |
Assignee: | AbbVie Inc. (North Chicago, IL) |
Application Number: | 16/654,442 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 11,246,866
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,246,866
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2016283018 | ⤷ Try a Trial | |||
Australia | 2016296709 | ⤷ Try a Trial | |||
Brazil | 112017028185 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |